A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV

NCT01448486 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Funding withdrawn based on unacceptably slow recruitment rate.

Conditions

Human Immunodeficiency Virus (HIV)
HIV Associated Neurocognitive Disorders (HAND)

Interventions

DRUG: Raltegravir

Sponsor

St Vincent's Hospital, Sydney

Collaborators

[object Object]